Objectives: Published cost estimates for cystic fibrosis (CF) are based on older data and do not reflect increased use of specialty drugs in recent years. We assessed recent trends in healthcare expenditures for CF patients in the United States (US) with employer-sponsored health insurance. 
Much pharmaceutical spending is on specialty drugs, defined in the US context as medications costing at least $1000 per prescription or per month. 3 Specialty drugs include orphan drugs that target rare diseases such as CF, which affects about 35 000 people in the United
States. 4 Specialty drugs for CF include pulmonary medications that treat chronic infection, airway mucus obstruction, and inflammation, and pancreatic enzyme products to treat malabsorption. Until recently, pancreatic enzymes as nutritional supplements were unregulated in the United States. After the U.S. Food and Drug Administration (FDA) began to require approval of marketing of pancreatic enzyme products on the basis of evidence of clinical efficacy and safety, FDA approved six pancreatic enzyme products for CF during 2009-2012. 5 CF has become a model system for precision medicine, which includes medications targeted to specific protein defects associated with individual mutations or genotypes. 6 In particular, new genomespecific biologic medications, namely cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies that target defects in the CFTR protein caused by specific mutations in the CFTR gene, have been introduced. Ivacaftor (Kalydeco™) was first approved by FDA in January 2012 for patients aged ≥6 years with a G551D CFTR mutation, about 4-5% of CF patients. 7, 8 FDA subsequently expanded its approved use to include nine additional mutations (February 2014), patients ≥2 years old (March 2015) and, most recently, an additional 23 mutations (May 2017). 9 Uptake of ivacaftor use following FDA approval was rapid, with roughly 80% of eligible patients initiating use in the first year. 10 A combination drug, lumacaftor/ivacaftor (Orkambi™) was approved in July 2015 for patients aged ≥12 years with the most common CFTR genotype (delF508 homozygous), 11 and the indication was expanded in 2016 to children aged 6-11 years. These two approved CFTR medications are an order of magnitude more expensive than other CF specialty drugs. 11 No studies have reported the contribution of spending on these products to overall expenditures for insured patients with CF, although one modeling study was published in 2016. 12 In this study, we describe current trends in health care expenditures for commercially insured patients with CF in the US. Table S2 ).
Outpatient expenditures were classified in this analysis into outpatient encounters, emergency room (with discharge home), laboratory tests, and durable medical equipment for respiratory support.
Per-person mean current calendar-year expenditures were calculated and graphed. Average annual growth rates were calculated through linear regression of the natural logarithm of annual mean or median expenditures on calendar year for specified time periods; the regression coefficient expresses the average exponential increase for that period. (Table 1 ). The administrative prevalence in children was similar to the birth prevalence of CF in the United States, estimated at 2.9 per 10 000 births. 4 The lower frequency of CF in adults in this sample is a product of both excess mortality and sample selection for relatively healthy adults with ESI.
| Overall expenditures
Spending Growth in spending on other specialty drugs, both pulmonary and pancreatic, was also rapid. Inflation-adjusted spending on pancreatic enzyme and pulmonary therapies grew by 17.1-17.3% and 9.1-9.2%
per year, respectively. Because growth in spending on CFTR modulators was even more rapid, the share of other specialty drugs fell from 72% of pharmaceutical spending in 2010 (56% for pulmonary drugs and 16% for pancreatic enzymes) to 42% in 2016 (28% for pulmonary and 14% for pancreatic enzymes).
The increases in per-patient spending on pancreatic enzyme and pulmonary products were largely accounted for by increased spending per filled prescription, which grew in inflation-adjusted terms by 12.8% and 7.4% per year. There were modest increases in the proportions of patients using pancreatic enzymes or pulmonary medications, from The role of specialty drugs as cost drivers in overall healthcare spending has attracted growing attention from stakeholders including insurers, self-insured employers, pharmacy benefit managers, and public policymakers. 3, 17 In 2015, specialty drugs accounted for almost 40% of drug spending in the United States, and is expected to reach 50% by 2018. 17 The increase in spending has ramifications for insurance benefit design, drug formularies, and coverage criteria. The high cost of treatments could also increase out-of-pocket spending for patients, which have implications for adherence to therapies and treatment decision-making.
Despite the notable increase in specialty drug spending for people with CF, it is important to consider the improvements in health outcomes that occurred during this period. Life expectancy continues to rise with the introduction of new therapies and advances in care delivery. Over the past decade, the CF Foundation has issued peerreviewed, evidence-based guidelines for chronic respiratory medications that support early use of CF-specific specialty medications. 18 Long-term use of specialty drugs, such as inhaled tobramycin and dornase alfa, has been linked to decreased mortality. 19 In addition, CF care centers adopting more aggressive monitoring in their patient populations have been shown to have better overall health outcomes. 20 Over this period, therefore, treatment complexity in CF has increased in both pediatric and adult patient populations. 21 Notably, a recent registry-based comparison of CF health outcomes found that children and young adults in the United States had better lung function than those in the United Kingdom, and that specialty drugs, such as dornase alfa, were much more commonly prescribed in the United States. 22 All of these factors that have improved health likely also contributed to the rise in pharmaceutical expenditures observed in this analysis.
Breakthrough drugs, such as ivacaftor, represent both the greatest promise for dramatic improvement in CF health outcomes and the largest impact on healthcare spending. Both ivacaftor and lumacaftor/ ivacaftor have proven efficacy in clinical trials, although the magnitude of clinical benefit in eligible populations in terms of improved lung function is greater for ivacaftor monotherapy than for lumacaftor/ ivacaftor. 8, 23 Effectiveness studies using real-world patient registry data have shown sustained benefits of ivacaftor in terms of slowing disease progression and improving nutritional status. 24 An analysis of MarketScan claims data found a two-thirds reduction in inpatient admissions with a CF diagnosis among patients who initiated ivacaftor therapy during 2012. health-related quality of life-is still unknown. Ongoing evaluation of these therapies is needed to ensure that increased spending on them is associated with optimal outcomes (i.e., the value proposition).
Researchers are expected to provide information on costs and outcomes to payers and other stakeholders so that decision makers can determine which clinical services provide good value. 26 The UK National
Health Service (NHS) in 2012 commissioned a health technology assessment of ivacaftor. 27 The incremental cost-effectiveness ratio (ICER) was calculated to be 10-15 times higher than the threshold range used, but within the range of other "ultra-orphan" medicines covered by the NHS. 28 On that basis, ivacaftor was approved for coverage.
Like any study using administrative healthcare data, this study has limitations. 29 One is the restriction to a convenience sample of private insurance plans sponsored by employers. Excluding those patients reduced mean expenditures for the remaining patients by 5%.
| CONCLUSIONS
Rapid growth in private expenditures for CF in recent years appears to be largely due to increases in specialty drug spending, particularly as new high-priced precision medicine therapies are being introduced.
Expenditures on the treatment of CF in the United States, as assessed through administrative private insurance claims, is increasingly dominated by specialty drugs. Ongoing evaluation of the benefits of existing and new therapies, as well as how they affect overall healthcare use, is needed to ensure patients receive high-quality, highvalue care. A challenge for researchers, though, is a lack of accurate information as to how much payers are actually spending on CF medications after taking into account discounts and rebates. 
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